Breaking News Instant updates and real-time market news.

BDX

Becton Dickinson

$170.31

-0.38 (-0.22%)

, ILMN

Illumina

$136.18

0.99 (0.73%)

07:08
11/29/16
11/29
07:08
11/29/16
07:08

Piper sees tax holiday as potential catalyst for Medical Diagnostics space

A repatriation tax holiday represents a potential catalyst for the Medical Diagnostics space, Piper Jaffray analyst William Quirk tells investors in a research note. Quirk notes that Becton Dickinson (BDX), Illumina (ILMN) and PerkinElmer (PKI) disclose cash held overseas and that all have highlighted share repurchases and acquisitions as priorities. He believes a repatriation event could be a catalyst for small lab deals. Acquisition targets include CareDx (CDNA), Genomic Health (GHDX), Oxford Immunotec (OXFD), Trovagene (TROV) and Veracyte (VCYT), Quirk tells investors.

BDX

Becton Dickinson

$170.31

-0.38 (-0.22%)

ILMN

Illumina

$136.18

0.99 (0.73%)

PKI

PerkinElmer

$50.94

-0.6 (-1.16%)

CDNA

CareDx

$3.75

-0.1 (-2.60%)

GHDX

Genomic Health

$30.91

-0.59 (-1.87%)

OXFD

Oxford Immunotec

$14.70

0.14 (0.96%)

TROV

Trovagene

$2.95

-0.15 (-4.84%)

VCYT

Veracyte

$7.68

-0.07 (-0.90%)

  • 29

    Nov

  • 30

    Nov

  • 04

    Dec

  • 07

    Dec

BDX Becton Dickinson
$170.31

-0.38 (-0.22%)

05/26/16
PIPR
05/26/16
NO CHANGE
PIPR
Piper sees limited impact from new European device tax rules
Piper Jaffray analyst William Quirk points out that the European Union announced it will issue new rules for medical devices and in vitro diagnostics in the near-to-mid term. The EU is looking to strengthen rules for clearing devices/tests for the market and increase existing device/test surveillance, Quirk tells investors in a research note. He believes the new rules should not inhibit well validated tests/devices from coming to market. As such, Quirk expects little impact to Piper's in vitro diagnostic coverage universe, namely Accelerate Diagnostics (AXDX), Becton Dickinson (BDX), Cepheid (CPHD), Hologic (HOLX), Quidel (QDEL) and Meridian Bioscience (VIVO).
09/23/16
SBSH
09/23/16
DOWNGRADE
Target $165
SBSH
Sell
Becton Dickinson downgraded to Sell from Neutral at Citi
Citi analyst Amit Hazan downgraded Becton Dickinson to Sell saying a cyclical U.S. slowdown will drive the company's organic growth below expectations. The analyst also sees a diminishing impact on Becton's growth from emerging markets. He cut his price target for the shares to $165 from $167.
09/23/16
09/23/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Twitter (TWTR) downgraded to Underperform from Sector Perform by RBC analyst Mark Mahaney, who cut his price target to $14 from $17. The research firm's survey of more than 1,100 advertising professionals and their attitudes towards Facebook (FB), Google (GOOG), Twitter and other high-profile names showed that, despite marketing budgets continuing to shift online, interest in the microblog platform appears to be declining. Of note, Twitter shares have surged this morning after CNBC's David Faber reported that Twitter is moving closer to selling itself and has received expressions of interest in a possible sale, although no deal is imminent. 2. Yum! Brands (YUM) downgraded to Outperform from Top Pick by RBC Capital analyst David Palmer based on valuation. His price target on Yum shares remains $97. 3. Becton Dickinson (BDX) downgraded to Sell from Neutral by Citi analyst Amit Hazan, who thinks a cyclical U.S. slowdown will push the company's organic growth below expectations. The analyst, who also sees a diminishing impact on Becton's growth from emerging markets, cut his price target for the shares to $165 from $167. 4. NextEra Energy (NEE) downgraded to Hold from Buy by Deutsche Bank analyst Jonathan Arnold, as he sees limited near-term upside with the shares up 23% year-to-date. "Extraordinarily frosty commentary" from two of three PUCT commissioners yesterday regarding NextEra's Oncor deal indicates an uphill battle in getting it approved, Arnold tells investors. 5. AVANGRID (AGR) downgraded to Underweight from Neutral by JPMorgan analyst Christopher Turnure, who thinks both the company's growth guidance and consensus expectations "appear ambitious." He lowered his price target for the shares to $41 and $44 and notes he does not have confidence in AVANGRID's near-term growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/18/16
LEER
11/18/16
NO CHANGE
Target $185
LEER
Market Perform
Becton Dickinson price target raised to $185 from $180 at Leerink
Leerink analyst Richard Newitter raised his price target for Becton Dickinson to $185 from $180 following the company's analyst event. Nonetheless, the analyst reiterates a Market Perform rating on the shares as he continues to believe there are better return/growth profiles elsewhere in his large cap coverage and thinks the valuation premium implied by his price target adequately gives credit for upside potential.
ILMN Illumina
$136.18

0.99 (0.73%)

10/11/16
JANY
10/11/16
DOWNGRADE
JANY
Sell
Illumina downgraded to Sell from Neutral at Janney Capital
10/11/16
10/11/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Comerica (CMA) downgraded to Market Perform from Outperform at FBR Capital with analyst Bob Ramsey citing valuation following the recent strength in the shares. 2. Charter downgraded to Neutral from Buy at MoffettNathanson with analyst Craig Moffett saying shares have risen sharply year-to-date, along with consensus estimates, and views shares as fairly valued. 3. BHP Billiton (BHP) downgraded to Neutral from Buy at UBS with the firm citing its expectations for lower iron ore and coal prices over the next six months. 4. Illumina (ILMN) downgraded to Sell from Neutral at Janney Capital and to Neutral from Buy at Citi. 5. KBR (KBR) downgraded to Sell from Neutral at Goldman with analyst Jerry Revich citing limited growth prospects due to outsized exposure to core LNG and greenfield ammonia capex cycles that are in the early stages of decline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/02/16
FANA
11/02/16
DOWNGRADE
Target $116
FANA
Underweight
Illumina downgraded to Underweight from Equal-Weight at First Analysis
First Analysis analyst Joseph Munda downgraded Illumina to Underweight saying the valuation is too high given management's "unconvincing arguments about the outlook," his concerns regarding overcapacity and a "continued lack of new products in the near-term pipeline." The analyst lowered his price target for the shares to $116 from $130 following Illumina's Q3 results.
11/10/16
LEER
11/10/16
INITIATION
Target $145
LEER
Market Perform
Illumina resumed with a Market Perform at Leerink
Leerink analyst Puneet Souda resumed coverage of Illumina with a Market Perform rating and $145 price target.
PKI PerkinElmer
$50.94

-0.6 (-1.16%)

06/24/16
CANT
06/24/16
NO CHANGE
CANT
'Brexit' slight negative for life science tools, diagnostics space, says Cantor
Cantor analyst Bryan Brokmeier believes that while industry fundamentals remain intact and the sector does not have a high exposure to the macro environment, tools companies do have high currency exposure and may face multiple contraction following the "Brexit" vote. With less exposure to market turmoil than molecular diagnostic companies, which trade at high multiples, Brokmeier prefers life science tools companies, adding that he is bullish on PerkinElmer (PKI) and Waters (WAT), which he sees as "more stable" businesses.
07/26/16
CANT
07/26/16
NO CHANGE
Target $173
CANT
Buy
Waters price target raised to $173 from $163 at Cantor
Cantor Fitzgerald analyst Bryan Brokmeier raised his price target for Waters Corporation (WAT) to $173 and recommends buying the stock following the company's "strong" Q2 results and raised guidance. The analyst keeps a Buy rating on the name. Regarding a read-through to Bruker (BRKR), Brokmeier notes that Waters' academic market was broadly weak during the quarter. He remains positive on the shares, but is hesitant to call Waters' quarter an incremental positive for Bruker. The analyst prefers shares of PerkinElmer (PKI), which he notes has a higher exposure to the biopharma end market.
08/05/16
MZHO
08/05/16
DOWNGRADE
Target $56
MZHO
Neutral
PerkinElmer downgraded to Neutral from Buy at Mizuho
Mizuho analyst Eric Criscuolo downgraded PerkinElmer to Neutral citing valuation following the company's Q2 results with the stock near his $56 price target. The analyst sees "no strong driver: to push the valuation higher.
09/22/16
UBSW
09/22/16
NO CHANGE
Target $61
UBSW
Buy
PerkinElmer still an underappreciated story, says UBS
UBS analyst Jonathan Groberg believes PerkinElmer remains an underappreciated story. The analyst said his buy thesis remains unchanged as management has executed well on its plan to streamline and invest in core businesses. Groberg reiterated its Buy rating and raised his price target to $61 from $56 on PerkinElmer shares, also citing expectations the company will be able to expand margins and the stock's compelling relative valuation.
CDNA CareDx
$3.75

-0.1 (-2.60%)

06/13/16
LEER
06/13/16
NO CHANGE
LEER
CMS price proposals for diagnostic tests a negative for most, says Leerink
Leerink analyst Dan Leonard expects several diagnostics stocks to underperform following proposed price cuts or low initial reimbursement rates by the Centers for Medicare and Medicaid Services, or CMS, for diagnostic tests. If finalized, the preliminary pricing would negatively impact CareDx (CDNA), Veracyte (VCYT), and InVitae (NVTA), the analyst tells investors in a research note, adding that he also sees an indirect negative read-through for Illumina (ILMN).
06/13/16
CANT
06/13/16
NO CHANGE
Target $13
CANT
Buy
Cantor sees 'flawed methodology' with new CMS rates
Cantor Fitzgerald analyst Bryan Brokmeier says shares of Veracyte (VCYT) may be under pressure this morning following Friday's release of a proposed gapfill Medicare reimbursement rate reduction on the company's Afirma GEC. Along with the 30% reduction on Afirma's GEC, the release from the Centers for Medicare and Medicaid Services resets rates on 15 other molecular diagnostic tests, including reductions in CareDx's (CNDA) AlloMap, which is down 74%, Genomic Health's (GHDX) Oncotype Dx Colon, which is down 73%, and Rosetta Genomics' (ROSG) Cancer Origin Test, which is down 57%, Brokmeier tells investors in a research note. The analyst, however, believes the preliminary proposed gapfill rate is based on a "flawed methodology" because it is the median proposed rate submitted by all Medicare Administrative Contractors, including those that have little or no experience administering claims on these tests, Brokmeier contends. He points out that Medicare represents approximately 20% of Afirma GEC test volume for Veracyte. Based on 2015 volume, the 30% Medicare rate reduction for Afirma would reduce total revenues by $3.7M or 7.5%, he adds. The analyst keeps a Buy rating on Veracyte with a $13 price target.
06/20/16
PIPR
06/20/16
NO CHANGE
PIPR
Final PAMA rule better than expected, says Piper Jaffray
Piper Jaffray analyst William Quirk says the final Protecting Access to Medicare Act published Friday by Centers for Medicare & Medicaid Services is better than expected. PAMA is delayed until 2018 from 2017 as expected, Quirk tells investors in a research note. Hospital labs will be required to submit private payer rates to CMS, a positive relative to prior expectations, the analyst notes. He views the decision as beneficial for Quest Diagnostics (DGX) and LabCorp (LH). Further, CMS will require labs to submit only in-network rates and out-of-network "final" rates, which is a positive for specialty labs who have in-network rates at or above Medicare including CareDx (CDNA), Genomic Health (GHDX), Myriad Genetics (MYGN), Oxford Immunotec (OXFD) and Veracyte (VCYT), Quirk writes.
07/07/16
PIPR
07/07/16
NO CHANGE
PIPR
New FDA recommendation positive for lab companies, says Piper Jaffray
Piper Jaffray analyst William Quirk says that the FDA has issued draft guidance to streamline its approval process for next-generation sequencing, or NGS, germline tests, which could be a substitute for a Premarket Notification or 510k. The analyst believes streamlined regulatory approaches for NGS tests are a positive for labs with NGS laboratory-developed tests such as CareDx (CDNA), Quest Diagnostics (DGX), Genomic Health (GHDX), LabCorp (LH), Myriad Genetics (MYGN), Natera (NTRA), Oxford Immunotec (OXFD), Sequenom (SQNM), Trovagene (TROV), and Veracyte (VCYT).
GHDX Genomic Health
$30.91

-0.59 (-1.87%)

06/21/16
LEER
06/21/16
NO CHANGE
Target $38
LEER
Outperform
Leerink remains confident on Genomic Health revenue acceleration story
Leerink analyst Dan Leonard remains confident that Genomic Health's revenue acceleration could lead to multiple expansion, adding that recent due diligence highlights efforts to drive growth in the core breast franchise. The analyst reiterates an Outperform rating and $38 price target on the shares.
OXFD Oxford Immunotec
$14.70

0.14 (0.96%)

06/24/16
PIPR
06/24/16
NO CHANGE
Target $25
PIPR
Overweight
Piper Jaffray positive on Imugen acquisition by Oxford Immunotec
Piper Jaffray analyst William Quirk says the acquisition of Imugen, a clinical laboratory focused on developing and performing specialized testing for tick-borne diseases, by Oxford Immunotec is a "good strategic fit" given call point overlap. Oxford's vision is to leverage the exiting sales force and marketing infrastructure to grow its revenue in the U.S., the analyst tells investors in a research note. Quirck also notes that Oxford has more costs than revenue in GBP and today's GBP/USD movements following the "Brexit" vote could be a net benefit. He reiterates an Overweight rating and $25 price target on Oxford's shares.
TROV Trovagene
$2.95

-0.15 (-4.84%)

09/30/16
CANT
09/30/16
NO CHANGE
CANT
Trovagene outlook has improved, says Cantor
After meeting with Trovagene's management, Cantor analyst Bryan Brokmeier is more upbeat on the stock. He says that the company's new strategy :"significantly reduces" its cash needs, provides it with multiple potential positive catalysts and reduces its competition. The analyst keeps an $8 price target and Buy rating on the shares.
08/08/16
CANT
08/08/16
UPGRADE
Target $7
CANT
Buy
Trovagene upgraded to Buy with $7 target at Cantor
Cantor Fitzgerald analyst Bryan Brokmeier upgraded Trovagene to Buy from Hold citing the company's accelerating clinical business. In Q2, the company increased the number of physicians on the platform to approximately 700 physicians from 550 in Q1, Brokmeier tells investors in a research note. He points out that Trovagene is also targeting new biopharma collaborations. The analyst raised his price target for the shares to $7 from $5.
08/08/16
CANT
08/08/16
UPGRADE
CANT
Buy
Trovagene upgraded to Buy from Hold at Cantor
VCYT Veracyte
$7.68

-0.07 (-0.90%)

09/08/16
CANT
09/08/16
NO CHANGE
Target $13
CANT
Buy
Cantor says buy Veracyte following draft local coverage determination
Cantor analyst Bryan Brokmeier recommends that investors buy shares of Veracyte following the announced draft local coverage determination, or LCD, for the company's Percepta Bronchial Genomic Classifier. The analyst says this draft LCD with Noridian Healthcare Solutions represents over 30M covered lives for its Percepta and represents more than 25% of the U.S. market opportunity. Further, Brokmeier believes other Medicare Administrative Contractors will follow Noridian's lead. The analyst reiterates a Buy rating and $13 price target on the shares.
10/18/16
CANT
10/18/16
NO CHANGE
CANT
Veracyte should be bought at current levels, says Cantor
After Veracyte preannounced higher than expected revenue, Cantor analyst Bryan Brokmeier says that the revenue beat indicates that the company's reimbursement trends are improving. The analyst thinks that the company is well-positioned to continue getting reimbursed for its tests, and he says that the stock's valuation is "compelling." The analyst recommends buying the shares at current levels.
11/14/16
LEER
11/14/16
INITIATION
Target $12
LEER
Outperform
Veracyte reinstated with an Outperform at Leerink
Leerink analyst Puneet Souda resumed coverage of Veracyte with an Outperform rating and $12 price target, saying it is gaining traction as reimbursement continues to tilt the scale.
11/22/16
LEER
11/22/16
NO CHANGE
Target $12
LEER
Outperform
CLFS 2017 rates a clear positive for Veracyte, says Leerink
Leerink analyst Puneet Souda notes that the Centers for Medicare and Medicaid Services, or CMS, released its Clinical Laboratory Fee Schedules, or CLFS, final determination or final pricing on a number of tests for 2017 including Veracyte's Afirma. The analyst sees the company's Afirma Thyroid FNA GEC pricing increase as a clear positive for Veracyte as it eliminates both near-term uncertainty and saves the company from an expected $1.6M impact in 2017. He reiterates an Outperform rating and $12 price target on the shares.

TODAY'S FREE FLY STORIES

ALNY

Alnylam

$42.25

1.445 (3.54%)

16:16
12/09/16
12/09
16:16
12/09/16
16:16
Hot Stocks
Breaking Hot Stocks news story on Alnylam »

Dodge & Cox reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

$NYE

NYSE Market Internals

16:16
12/09/16
12/09
16:16
12/09/16
16:16
Technical Analysis
NYSE market internals summary »

Breadth is mixed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVO

Cenveo

$6.84

-0.16 (-2.29%)

16:16
12/09/16
12/09
16:16
12/09/16
16:16
Hot Stocks
Breaking Hot Stocks news story on Cenveo »

Brigade Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

16:16
12/09/16
12/09
16:16
12/09/16
16:16
Technical Analysis
NASDAQ market internals summary »

Volume is very heavy for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLRB

Cellectar Biosciences

$1.33

-0.04 (-2.92%)

16:15
12/09/16
12/09
16:15
12/09/16
16:15
Hot Stocks
Cellectar, INC Research enter into Work Order »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSW

International Seaways

$14.40

0.86 (6.35%)

16:12
12/09/16
12/09
16:12
12/09/16
16:12
Hot Stocks
Breaking Hot Stocks news story on International Seaways »

Cyrus Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BFS

Saul Centers

$66.45

-0.96 (-1.42%)

16:09
12/09/16
12/09
16:09
12/09/16
16:09
Hot Stocks
Saul Centers raises quarterly dividend 8.5% to 51c from 47c per share »

The dividend is to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASNA

Ascena Retail

$8.04

-0.07 (-0.86%)

16:08
12/09/16
12/09
16:08
12/09/16
16:08
Hot Stocks
Ascena Retail names David Jaffe chairman of the board »

Ascena Retail announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MORN

Morningstar

16:08
12/09/16
12/09
16:08
12/09/16
16:08
Hot Stocks
Morningstar raises quarterly dividend to 23c from 22c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAND

Sandstorm Gold

$3.83

-0.19 (-4.73%)

16:07
12/09/16
12/09
16:07
12/09/16
16:07
Syndicate
Breaking Syndicate news story on Sandstorm Gold »

Sandstorm Gold files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACIU

AC Immune

$14.93

2.88 (23.90%)

, RHHBY

Roche

$27.86

0.78 (2.88%)

16:05
12/09/16
12/09
16:05
12/09/16
16:05
Hot Stocks
AC Immune partner Genentech presents 'important' data on Alzheimer's therapy »

AC Immune (ACIU)…

ACIU

AC Immune

$14.93

2.88 (23.90%)

RHHBY

Roche

$27.86

0.78 (2.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDVX

Medovex

$1.50

0.03 (2.04%)

16:03
12/09/16
12/09
16:03
12/09/16
16:03
Hot Stocks
Breaking Hot Stocks news story on Medovex »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDC

Belden

$78.79

-1.69 (-2.10%)

16:01
12/09/16
12/09
16:01
12/09/16
16:01
Hot Stocks
Belden extends shareholder rights agreement »

Belden announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GENE

Genetic Technologies

$1.19

-0.01 (-0.83%)

15:59
12/09/16
12/09
15:59
12/09/16
15:59
Hot Stocks
Breaking Hot Stocks news story on Genetic Technologies »

CVI Investments reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLO

Flowers Foods

$19.26

2.2325 (13.11%)

15:53
12/09/16
12/09
15:53
12/09/16
15:53
Recommendations
Flowers Foods analyst commentary  »

Flowers Foods settlement…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$54.22

-0.21 (-0.39%)

15:50
12/09/16
12/09
15:50
12/09/16
15:50
Options
Halliburton Dec 48.5 puts for a nickel per contract »

Halliburton Dec 48.5 puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

BIIB

Biogen

$289.54

4.24 (1.49%)

15:43
12/09/16
12/09
15:43
12/09/16
15:43
Recommendations
Biogen analyst commentary  »

Piper says Biogen still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLO

Valero

$67.84

-0.535 (-0.78%)

15:40
12/09/16
12/09
15:40
12/09/16
15:40
Options
Higher option volume in Valero driven by downside put purchases »

Higher option volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKLN

Skyline Medical

$2.94

-0.01 (-0.34%)

15:36
12/09/16
12/09
15:36
12/09/16
15:36
Syndicate
Skyline Medical files to sell 1.925M units »

Each unit consisting of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMNY

Helios and Matheson

$4.26

-0.08 (-1.84%)

15:35
12/09/16
12/09
15:35
12/09/16
15:35
Hot Stocks
Farnsworth acquires 1.74M Helios and Matheson shares as part of merger pact »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLO

Flowers Foods

$19.10

2.07 (12.16%)

15:32
12/09/16
12/09
15:32
12/09/16
15:32
Upgrade
Flowers Foods rating change  »

Flowers Foods upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBA

Walgreens Boots Alliance

$84.28

-0.71 (-0.84%)

, RAD

Rite Aid

$8.20

0.045 (0.55%)

15:25
12/09/16
12/09
15:25
12/09/16
15:25
Periodicals
Walgreens near finalizing Rite Aid divestiture package, CTFN reports »

Walgreens (WBA) is…

WBA

Walgreens Boots Alliance

$84.28

-0.71 (-0.84%)

RAD

Rite Aid

$8.20

0.045 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

BAS

Basic Energy

$0.44

-0.0039 (-0.89%)

15:19
12/09/16
12/09
15:19
12/09/16
15:19
Hot Stocks
Breaking Hot Stocks news story on Basic Energy »

Basic Energy trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
12/09/16
12/09
15:16
12/09/16
15:16
Technical Analysis
NYSE market internals summary »

Breadth is mixed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:16
12/09/16
12/09
15:16
12/09/16
15:16
Technical Analysis
NASDAQ market internals summary »

Volume is heavy for this…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.